We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
The Paediatric Oncology and Haematology Department is a leader in treating cancer in childhood and adolescence. Of every 1,000 new cases of childhood cancer detected every year in Spain, 200 are diagnosed in Catalonia.
According to data from the Spanish Register of Tumours in Infants (RETI), ours it the Department that treats the most children in Spain, and is the leading centre for the transplant of haematopoietic progenitors or stem cells (better known as "bone marrow transplants"), having performed more than 1200 such operations. The Paediatric Oncology and Haematology Day Hospital handles up to 3,600 treatment visits a year and up to 7,600 visits for consultations.
Our experience, staff and advanced technological prowess mean our Department can offer multidisciplinary, comprehensive care to patients and their families, covering all diagnostic procedures and offering the most advanced treatments. We are a self-sufficient department when it comes to applying the latest care techniques in this field, and we also have resources to carry out research in such diseases.
Childhood cancer is the leading cause of child mortality due to illness in children more than one year old. Survival is currently around 80%, but it is essential we advance research into the disease to achieve more effective treatments.
The Department has a multiprofessional team of staff made up of doctors, nurses and others. Their functions include:
The Group for Translational Research into Childhood and Adolescent Cancer is focused on research for new treatment targets or molecule targets (the place in the organism a drug acts on), based on the most advanced knowledge available on the biology of paediatric cancers. The Group has identified and will continue to work on new molecular targets for sarcomas (cancer that originates in connective tissue cells) and tumours of the nervous system.
Collaborations with the biotechnology industry are currently being established and consolidated in order to develop new drugs capable of inhibiting pro-oncogenic processes, such as invasion and proliferation, in order to provide patients with alternative therapy options.
As an international centre of reference, our Department belongs to the International Network of Excellence in the Treatment of Cancer in Children and Adolescents. We carry out clinical work, research and teaching activity in coordination with international scientific societies: International Society of Paediatric Oncology (SIOP), European Society for Blood and Marrow Transplantation (EBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and national societies: Spanish Society of Paediatric Haematology and Oncology (SEHOP), Programme for the Study and Treatment of Malignant Haemopathy (Pethema).
Based on data from the National Registry of Child Tumours, our hospital diagnoses and treats the most children. Their survival rates are comparable to the most prestigious international centres of excellence. Our centre was the first in Spain to obtain JACIE accreditation (Joint Accreditation Committee ISCT and EBMT), the most prestigious in our field.
The Haematopoietic Progenitors Transplant Unit is the most active of its kind in Spain, with an average of 40 transplants per year. We perform all kinds of transplants, and are pioneers in complex cases, such as unrelated donors and umbilical cord blood transplants. We also perform transplants in cases of malignant oncohaematological diseases, acquired medullary aplasias and congenital pathologies such as immunodeficiencies, haemoglobinopathies, metabolopathies and medullary insufficiencies.
We should highlight our translational research group, which applies the knowledge acquired from basic research to the prevention and treatment of clinical cases in childhood cancer and haematological diseases, which contributes to better diagnosis, prognosis, treatment and control of such diseases. The Department has a Clinical Trials Unit for Innovative Treatments and belongs to the Innovative Therapy in Cancer Children (ITCC) group.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.